Takeda, Astellas Found New JV To Support Japanese Bioventures

Collab With SMBC

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Takeda, Astellas and SMBC will establish an unnamed joint venture in Shonan iPark in mid-2024.
Takeda, Astellas and SMBC to establish new JV in Japan's Shonan iPark in mid-2024 • Source: Shutterstock

While some parts of the Japanese government have been implementing policy measures to help fund more bioventures, several large key domestic industry players in the country have joined hands to offer another form of support.

Takeda Pharmaceutical Co. Ltd. and Astellas Pharma, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Focus On Asia